Study uncovers new genetic risk factors for age-related macular degeneration, a leading cause of vision loss in adults.
Study demonstrates two different types of deposits in the retina that appear to contribute to age-related macular degeneration.
Lab-created retinal cells created from human stem cells can reach out and connect to neighboring cells, a new study reports. The cells have the capacity to replace damaged retinal cells and carry sensory information. The findings could pave the way for clinical trials for the treatment of a range of diseases associated with vision loss and blindness.
More severe COVID-19 outcomes associated with age-related macular degeneration likely arise from a genetic predisposition in addition to higher levels of Pdgf in blood serum.
Using patients' stem cells, researchers used 3D bioprinting to create and produce eye tissue. The advance could provide an unending supply of tissue to study, and ultimately cure retinal diseases and age-related macular degeneration.
Transcranial direct current stimulation can help improve reading for those with age-related macular degeneration.
Researchers induced non-neural cells that mimic ganglion cells in the eyes of mice, effectively reducing the impact of certain eye diseases. They hope to next replicate their technique in humans in order to help restore vision lost due to eye diseases.
People with subretinal drusenoid deposits (SDD), a form of age-related macular degeneration, are more likely to have underlying heart damage as a result of heart failure or heart attacks, or other forms of cardiovascular disease associated with increased stroke risk.
A new study reports regular usage of medications to control type 2 diabetes and lower cholesterol may decrease the risk of developing age-related macular degeneration.
Researchers have developed a new ophthalmological device that can detect degenerative visual problems such as age-related macular degeneration long before the onset of the first symptoms.
Determining the structure of vitronectin, a protein implicated in age-related macular degeneration and some neurodegenerative disorders, and using pressure to alter the protein shape may help in the development of new treatments for AMD.
A new study reports that a new gene therapy shows promise in treating dry age-related macular degeneration. The gene therapy, ophNdi1, directly targets mitochondrial function that is malfunctioning in AMD.
